Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Opioid-use Disorder Clinical Trial

Official title:

A Pilot Study to Permit Opioid Treatment Program Physicians to Prescribe Methadone Through Community Pharmacies for Their Stable Methadone Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04308694
• Other study ID #: Pro00103270
• Secondary ID: 3U01DA046910-02S
• Status: Completed
• Phase: Early Phase 1
• Start date: August 6, 2020
• Est. completion date: January 18, 2021

Study information

• Verified date: March 2022
• Source: Friends Research Institute, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching goal of this pilot study is to explore the feasibility, acceptability, and patient/provider satisfaction of pharmacy-based administration and dispensing of methadone for opioid use disorder. The results gained will inform the development of a future multisite randomized clinical trial.

Description:

The study will use a non-randomized, prospective, single group design. Twenty long-term, clinically-stable methadone maintenance treatment (MMT) patients who receive between 6- and 13-days methadone take-home doses will be enrolled in the study where their methadone take-home administration and dispensing will be transferred to a community pharmacy for 3 months. Participants will also complete three follow-up assessments at 1-month, 2-months, and 3-months after the baseline visit to collect clinical and safety information since the previous assessment. Primary outcomes will be focused on feasibility measures (recruitment, accessibility to methadone treatment, substance use, medication call back success, and retention in treatment). Secondary outcomes will be focused on self-reported satisfaction measures from MMT providers (e.g., physician, physician assistant, nurse, and counselor) pharmacists, and patient participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 18, 2021
• Est. primary completion date: January 5, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient aged 18 or older receiving methadone treatment at Morse Clinic in Raleigh or Zebulon, NC.

• Able to provide informed written consent to participate in the pilot study.

• Receiving a stable methadone dose between 5 mg and 160 mg.

• Having all negative drug tests (except for prescribed methadone and ethanol) at the OTP for the past 12 months.

• No missed call-backs in the past 12 months.

• No signs/symptoms of a co-occurring major mental illness (i.e., thought disorder, thoughts of harm to self or others, delusions or hallucinations, cognitive impairment compromising informed consent to study procedures and requirements).

• Meeting the federal and state regulations for eligibility to receive between 6- and 13-days of take-home methadone and receiving this level of take-home doses at the time of study enrollment.

• If female, using adequate birth control methods.

Exclusion Criteria:

• Have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study.

• Have chronic pain requiring ongoing pain management with opioid analgesics.

• Prisoner status or pending legal action that could prevent participation in study activities

• Legal order for treatment (e.g., parole, probation, or pre-trial)

• Pregnant or breastfeeding at the time of screening.

Related Conditions & MeSH terms

• Opioid-Related Disorders
• Opioid-use Disorder

Intervention

Drug:
• Pharmacy-based methadone administration and dispensing
Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.

Locations

Country	Name	City	State
United States	Health Park Pharmacy	Raleigh	North Carolina
United States	Morse Clinic of North Raleigh	Raleigh	North Carolina
United States	Morse Clinic of Zebulon	Zebulon	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Friends Research Institute, Inc.	Duke Health, National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment Rate	The recruitment rate will be assessed on a monthly basis (e.g, Month 1, 2 and 3) until the enrollment target is reached. The recruitment rate is operationalized as the total number of participants consented in one month.	3 months
Primary	Treatment Adherence	Adherence to pharmacy-based methadone treatment will be defined as the percentage of methadone take-home doses dispensed at the pharmacy out of the total number of take home doses prescribed.	Up to 3 months per participant
Primary	Treatment Retention	Treatment retention will be determined by the percentage of participants who remain in treatment at the pharmacy during the 3-month follow-up phase.	Up to 3 months per participant
Primary	Opioid and Other Substance Use	The percentage of positive urine drug screens over the study duration will be examined.	Up to 3 months per participant
Secondary	Treatment Satisfaction	Participant satisfaction with treatment delivery will be measured on a monthly basis and a percentage of overall monthly ratings (combined) of satisfied or very satisfied will be calculated.	Over 3 months of treatment
Secondary	Adverse Events	We will measure the prevalence of any fatal or non-fatal substance-related overdose and any substance-related emergency department visit or hospitalization.	Up to 3 months per participant
Secondary	Percentage of Participants With Methadone Call Backs With Evidence of Tampering.	Percentage of participants with call backs with evidence of methadone tampering.	3 months